Further studies will be necessary to clarify the immune pathogenesis of and possible specific treatments (such as anti-tumor necrosis factor, anti-interleukin-6, and anti-interleukin-1 blockers) (29,32) for this intriguing syndrome, particularly in immunocompromised MIS-C pediatric patients. This evidence concerns the gene TNF and COVID-19–associated multisystem inflammatory syndrome in children.